IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases
DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing...